Infectious Diseases (all articles)
Review: “Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19
7 Feb, 2021 | 21:13h | UTC“Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19 – Anesthesia
Report: The state of the world’s antibiotics report in 2021
7 Feb, 2021 | 20:49h | UTCCommentary: Report highlights lack of progress against antimicrobial resistance – CIDRAP
SR/MA: Colistin nephrotoxicity
5 Feb, 2021 | 01:21h | UTC
Opinion: Vaccine Nationalism Harms Everyone and Protects No One
5 Feb, 2021 | 01:45h | UTCVaccine Nationalism Harms Everyone and Protects No One – Foreign Policy
Related: Jeremy Farrar: Until we are all safe, no one is safe. Covid is a global problem – The Guardian AND Covid-19: WHO warns against “vaccine nationalism” or face further virus mutations – The BMJ AND ‘Vaccine nationalism’ threatens global plan to distribute COVID-19 shots fairly – Science AND WHO chief warns against ‘catastrophic moral failure’ in COVID-19 vaccine access – United Nations
NIH Treatment Guideline Update: “there are insufficient data to recommend either for or against the use of tocilizumab or sarilumab for the treatment of COVID-19”
5 Feb, 2021 | 01:44h | UTC
Study: Adults between 20 and 49 years responsible for most Covid-19 spread
5 Feb, 2021 | 01:43h | UTCAge groups that sustain resurging COVID-19 epidemics in the United States – Science
Commentaries: Adults 20 to 49 may have driven 72% of US COVID-19 surges – CIDRAP AND Younger adults responsible for most of COVID-19 spread: Study – ABC News
Study: Single dose Pfizer Covid-19 vaccine effectiveness estimated at 90% after 21 days
5 Feb, 2021 | 01:43h | UTCCommentaries: One Pfizer/BioNTech jab gives ‘90% immunity’ from Covid after 21 days – The Guardian AND Expert reaction to preprint reanalysing study of real-world Pfizer vaccination outcomes after one dose from Israel – Science Media Centre
Commentary on Twitter
A study on "real world" effects of vaccination in Israel
? Single dose 90% effective at 21d ?
"…results coming from Israel support the UK policy of extending the gap between doses by showing that a single dose can give a high level of protection."https://t.co/smnZUPJkZp
— Alasdair Munro (@apsmunro) February 4, 2021
Phase 1/2 Clinical Trial: CoronaVac is safe and well tolerated in older adults. Neutralizing antibodies were detected in over 90% of participants in all groups
5 Feb, 2021 | 01:41h | UTCCommentary: Inactivated COVID-19 vaccines to make a global impact – The Lancet Infectious Diseases
Commentary on Twitter
Second phase 1/2 trial published for Sinovac's CoronaVac, inactivated vaccine (both in China): the first was in adults to age 59. This one is 422 people aged 60+. Signs of immunity similar to the younger group, very low rate of adverse events https://t.co/ZQWknrK7Ry (No protocol)
— Hilda Bastian, PhD (@hildabast) February 4, 2021
New COVID-19 vaccines: here’s how the promising Novavax and Johnson & Johnson jabs work
5 Feb, 2021 | 01:41h | UTC
Dialysis patients have 4-fold greater risk of dying from COVID-19
5 Feb, 2021 | 01:39h | UTCNews Release: Dialysis patients have 4-fold greater risk of dying from COVID-19 – Canadian Medical Association Journal
Original Study: COVID-19 in patients undergoing long-term dialysis in Ontario – Canadian Medical Association Journal
Why the WHO won’t call it the ‘U.K. variant’, and you shouldn’t either
5 Feb, 2021 | 01:40h | UTCWhy the WHO won’t call it the ‘U.K. variant’, and you shouldn’t either – CTV News
Related: The world needs a single naming system for coronavirus variants – Nature
Policy Statement: Antibiotic Stewardship in Pediatrics
4 Feb, 2021 | 01:21h | UTCAntibiotic Stewardship in Pediatrics – Pediatrics
Commentary: Guidance Provided for Antibiotic Stewardship in Pediatrics
WHO: Consecutive drop in new COVID-19 cases ‘encouraging news’
4 Feb, 2021 | 01:37h | UTCConsecutive drop in new COVID-19 cases ‘encouraging news’: WHO – UN News
UK Biobank study shows that COVID-19 antibodies remain for at least 6 months post-infection for the vast majority of people who have had the virus
4 Feb, 2021 | 01:32h | UTCCommentary: Covid: Antibodies last at least six months in most – BBC
RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19
4 Feb, 2021 | 01:39h | UTCInvited Commentary: Azithromycin, RECOVERY, and the power of large, simple trials – The Lancet
Study shows the viral load of index cases is a leading driver of SARS-CoV-2 transmission
4 Feb, 2021 | 01:35h | UTCCommentary: Understanding the drivers of transmission of SARS-CoV-2 – The Lancet Infectious Diseases
Racing the virus: Why tweaking vaccines to fight variants won’t be simple
4 Feb, 2021 | 01:28h | UTCRacing the virus: Why tweaking vaccines to fight variants won’t be simple – Reuters
Video (3 min): Sinovac and Sinopharm – what do we know about the Chinese vaccines?
4 Feb, 2021 | 01:31h | UTCSinovac and Sinopharm – what do we know about the Chinese vaccines? – BBC
[Preprint] Meta-analysis: More than 50 Long-term effects of COVID-19
4 Feb, 2021 | 01:26h | UTCMore than 50 Long-term effects of COVID-19: a systematic review and meta-analysis – medRxiv
Commentary: 80% of COVID-19 Patients May Have Lingering Symptoms, Signs — More than 50 effects persisted after acute infection, meta-analysis shows – MedPage Today (free registration required)
The COVID-19 vaccine in pregnancy: risks, benefits, and recommendations
4 Feb, 2021 | 01:30h | UTCRelated: Pregnancy, breastfeeding and the SARS-CoV-2 vaccine: an ethics-based framework for shared decision-making AND The Coronavirus Vaccine Presents a Dilemma for Pregnant Women – The New Yorker
Systematic review: No evidence that patients with asthma are at increased risk of COVID-19 diagnosis, hospitalization or death
4 Feb, 2021 | 01:24h | UTC
Randomized trial: Chlorhexidine + alcohol better at prevention of short-term peripheral venous catheter infection compared to iodine + alcohol. Innovative devices were associated with less catheter failure
3 Feb, 2021 | 01:26h | UTC
The AstraZeneca vaccine and over-65s: we may not have all the data yet, but limiting access could be counterproductive
3 Feb, 2021 | 01:46h | UTC
Oxford/AstraZeneca study supports UK decision to delay second doses
3 Feb, 2021 | 01:47h | UTCOxford/AstraZeneca study supports UK decision to delay second doses – Financial Times
Original study (preprint): Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
See also: Single dose of AstraZeneca vaccine could cut transmission by 67% – The Guardian AND Oxford vaccine could substantially cut spread – BBC
Commentary on Twitter (thread – click for more)
NEW: fresh data from trials in Brazil, South Africa and the UK shows the Oxford/AstraZeneca vaccine is highly effective with a 12 week gap between doses.
Efficacy is in fact much higher with a 12 week interval than a shorter gap
Story by @donatopmancini: https://t.co/PK4NHhGHeH pic.twitter.com/W3urxSECKL
— John Burn-Murdoch (@jburnmurdoch) February 2, 2021
Russia’s Sputnik V COVID-19 vaccine candidate appears safe and is 91.6% effective
3 Feb, 2021 | 01:49h | UTCCommentaries: Sputnik V COVID-19 vaccine candidate appears safe and effective – The Lancet AND Russia’s “Sputnik V” COVID Vaccine Makes Strong 91.6 % Efficacy Showing In Peer-Reviewed Trial Results – Health Policy Watch AND Russia’s COVID vaccine 92% effective, even in those over 60 – CIDRAP AND Russia’s Sputnik V vaccine has 92% efficacy in trial – BBC AND Expert reaction to study looking at preliminary efficacy and safety results from interim analysis of Russian COVID-19 phase 3 vaccine (Sputnik) trial – Science Media Centre
Commentary on Twitter
NEW—Interim analysis of Russian #COVID19 #vaccine phase 3 trial involving nearly 20,000 participants suggests a two-dose regimen has an efficacy of 91.6% against symptomatic #COVID19. No serious adverse events were deemed to be associated with vaccination. https://t.co/40sM7f2nbS pic.twitter.com/Hzrs34uCWr
— The Lancet (@TheLancet) February 2, 2021